We are live on ! Find out more
STSA

Satsuma Pharmaceuticals

Delisted

STSA was delisted on the 7th of June, 2023.

32 hedge funds and large institutions have $94.2M invested in Satsuma Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

1.04% less ownership

Funds ownership: 73.19% → 72.15% (-1%)

11% less funds holding

Funds holding: 36 → 32 (-4)

57% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 7

66% less capital inflows, than outflows

Capital inflows: $1.1M | Capital outflows: $3.2M

Holders
32
Holders Change
-4
Holders Change %
-11.11%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
8
Reduced
8
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

STSA Hedge Fund Activity: Q2 2022 in Review

32 of the 5,961 institutional investors tracked by Wall St. Rank reported a position in Satsuma Pharmaceuticals (STSA) for Q2 2022, worth a combined $94.2M — up 7.5% from $87.7M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of STSA and 3 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 8 added.

The largest buyer was Samlyn Capital, adding an estimated $526K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $1.8M sold.

  • 32 institutional investors held Satsuma Pharmaceuticals (STSA) as of Q2 2022, down from 36 in Q1 2022.
  • Funds reported $94.2M of Satsuma Pharmaceuticals stock for Q2 2022, up 7.5% quarter-over-quarter.
  • 3 funds opened new Satsuma Pharmaceuticals positions in Q2 2022 and 7 closed out, a net change of -4 holders.
  • The largest Satsuma Pharmaceuticals buyer in Q2 2022 was Samlyn Capital, an estimated $526K added.
  • The largest Satsuma Pharmaceuticals seller in Q2 2022 was Ghost Tree Capital, an estimated $1.8M sold.

Based on aggregated 13F filings for Q2 2022.